- Stocks
- Pharma & Healthcare
- Kilitch Drugs (India)
Kilitch Drugs (India) share price
NSE: KILITCHPharma & HealthcareDrug Manufacturers - Specialty & Generic
Kilitch Drugs (India) at a glance
Kilitch Drugs (India) (NSE: KILITCH) closed at ₹215.00 on 30 Sep 2026. With a market capitalisation of ₹752 Cr, it ranks 1591st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 24.2× trailing earnings, against a return on equity of 10.8% in FY26. Over the past year the share price has risen 22.8%. Its 52-week range is ₹117.25 (30 Mar 2026) to ₹232.50 (24 Sep 2026); the last close is 7.5% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹90 Cr (+46.3% year on year) and net profit ₹15 Cr (+45.6%), on a consolidated basis. Promoters held 63.77% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹752 CrRank 1591 on NSE
- P/E (trailing)
- 24.2×
- Price to book
- 1.59×FY26
- EPS (TTM)
- ₹13.59to Q4 FY26
- ROE
- 10.8%FY26
- ROCE
- 13.2%FY26
- Debt to equity
- 0.32FY26
- Net profit margin
- 12.5%FY26
- Book value / share
- ₹79.99FY26
- 52-week high
- ₹232.5024 Sep 2026
- 52-week low
- ₹117.2530 Mar 2026
- 1-year return
- +22.8%
- RSI (14-day)
- 64.3
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.92% | −3.0% | +22.5% | +8.9% | +22.8% |
Kilitch Drugs (India) quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹33 Cr | ₹47 Cr | ₹56 Cr | ₹61 Cr | ₹43 Cr | ₹49 Cr | ₹54 Cr | ₹90 Cr |
| Revenue YoY | −8.5% | +15.2% | +76.7% | +36.6% | +29.0% | +3.1% | −4.2% | +46.3% |
| Net profit | ₹0 Cr | ₹9 Cr | ₹6 Cr | ₹10 Cr | ₹2 Cr | ₹8 Cr | ₹4 Cr | ₹15 Cr |
| Net profit YoY | −96.4% | +69.2% | +222.4% | +177.7% | +1,954.5% | −6.6% | −23.0% | +45.6% |
| Net margin | 0.3% | 18.1% | 10.0% | 16.7% | 5.2% | 16.4% | 8.0% | 16.6% |
| EPS | ₹0.83 | ₹5.36 | ₹3.71 | ₹6.47 | ₹1.88 | ₹4.97 | ₹2.50 | ₹4.24 |
Kilitch Drugs (India) financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹69 Cr | ₹114 Cr | ₹140 Cr | ₹154 Cr | ₹198 Cr | — |
| Operating profit | ₹5 Cr | ₹10 Cr | ₹12 Cr | ₹19 Cr | ₹34 Cr | — |
| Net profit | ₹4 Cr | ₹6 Cr | ₹8 Cr | ₹14 Cr | ₹25 Cr | — |
| EPS (₹) | ₹2.00 | ₹5.00 | ₹7.00 | ₹9.00 | ₹17.00 | — |
| Cash from operations | ₹46 Cr | ₹6 Cr | ₹3 Cr | −₹0 Cr | ₹18 Cr | — |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹28 Cr | ₹59 Cr |
| Shareholders' equity | ₹127 Cr | ₹139 Cr | ₹152 Cr | ₹176 Cr | ₹202 Cr | ₹280 Cr |
Kilitch Drugs (India) shareholding pattern
| Holder | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 25 Mar 2026 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 69.23% | 63.77% | 63.77% | 63.77% | 63.77% | 63.77% |
| Foreign institutions | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.12% |
| Domestic institutions | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Non-institutions | 30.76% | 36.23% | 36.23% | 36.22% | 36.22% | 36.11% |
Kilitch Drugs (India) vs peers
The listed Pharma & Healthcare companies nearest to Kilitch Drugs (India) by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| ANUHPHRAnuh Pharma | ₹80.29 | +0.68% | +0.4% | ₹805 Cr | 19.6 | — |
| KILITCHKilitch Drugs (India) | ₹215.00 | −0.92% | +22.8% | ₹752 Cr | 24.2 | — |
| VIKRAMTHVikram Thermo | — | — | — | ₹728 Cr | — | — |
| ZIMLABZim Laboratories | ₹133.50 | +2.30% | +92.4% | ₹715 Cr | 112.2 | — |
| VALIANTLABValiant Laboratories | ₹131.05 | −2.00% | +56.4% | ₹712 Cr | — | — |
| AMANTAAmanta Healthcare | ₹182.55 | −3.26% | +37.4% | ₹709 Cr | 42.2 | — |
| GAUDIUMIVFGaudium IVF and Women Health | ₹95.11 | +1.07% | — | ₹692 Cr | 24.3 | — |
Ask anything about Kilitch Drugs (India)
Pivot answers on the live chart with evidence you can check, and tests strategies against KILITCH's own history. Try: “Why has KILITCH moved over the last three months?” · “Backtest a 50-day moving-average crossover on KILITCH over five years” · “Compare KILITCH with ANUHPHR on margins and valuation”
Frequently asked questions about Kilitch Drugs (India)
What is the share price of Kilitch Drugs (India) today?
Kilitch Drugs (India) (NSE: KILITCH) last closed at ₹215.00 on 30 Sep 2026. Its 52-week high is ₹232.50 and its 52-week low is ₹117.25.
What is the market cap of Kilitch Drugs (India)?
Kilitch Drugs (India)'s market capitalisation is ₹752 Cr (₹752 Cr) at the 22 Oct 2026 close, ranking 1591st among the NSE companies Pivot tracks.
What is the P/E ratio of Kilitch Drugs (India)?
Kilitch Drugs (India) trades at a trailing P/E of 24.2. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 42.2.
What is the ROE and ROCE of Kilitch Drugs (India)?
Return on equity was 10.8% in FY26 and return on capital employed was 13.2% in FY26 (consolidated figures).
Is Kilitch Drugs (India) a debt-free company?
No. Kilitch Drugs (India)'s debt-to-equity ratio was 0.32 in FY26, with total debt of ₹59 Cr.
What were Kilitch Drugs (India)'s latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Kilitch Drugs (India) reported revenue of ₹90 Cr, +46.3% year on year, and net profit of ₹15 Cr, +45.6% year on year.
How has Kilitch Drugs (India) stock performed over the last year?
Kilitch Drugs (India)'s share price has risen 22.8% over the past year, +8.9% over three months and +22.5% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Kilitch Drugs (India)?
As of 30 Jun 2026: promoters 63.77%, foreign institutions 0.12%, domestic institutions 0.00%, non-institutions 36.11%.
Who are Kilitch Drugs (India)'s competitors?
The listed Pharma & Healthcare companies closest to Kilitch Drugs (India) by market cap are Anuh Pharma, Vikram Thermo, Zim Laboratories, Valiant Laboratories, Amanta Healthcare and Gaudium IVF and Women Health.
Is Kilitch Drugs (India) a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Kilitch Drugs (India)'s price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on KILITCH against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 30 Sep 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with K · all NSE stocks · this page as text